hgt-logo
CIRS
language
中文
Log in
Home/News/Details

Malaysia NPCB Updates the Approved Biosimilars

Jan 09, 2024
Malaysia
Pharmaceutical
Favorites
Share
Unlock exclusive content and benefits? Sign up for free today!

The pharmaceutical industry is one of the emerging sectors in Malaysia. The products produced in Malaysia are divided into four categories: prescription drugs, over-the-counter (OTC) drugs, traditional medicines, and health and dietary supplements.

In Malaysia, the National Pharmaceutical Regulatory Agency (NPCB) is responsible for the supervision of generic medicines and the Pharmaceutical Services Division (PSD) is responsible for the quality, efficacy and safety of pharmaceuticals.

On January 4, 2024, NPCB updated the List of Approved Biosimilars, which provides the details of approved active substances to ensure the safety use of biosimilars. 15 active substances are added to the List: Adalimumab, Bevacizumab, Enoxaparin sodium, Erythropoietin (Epoetin Alfa), Etanercept, Filgrastim, Human Insulin, Infliximab, Insulin Aspart, Insulin Glargine, Pegfilgrastim, Rituximab, Somatropin, Teriparatide, and Trastuzumab. The List also specifies the product name, registration number, and its manufacturer. This measure may enhance the market competition and reduce the risk of using unqualified or harmful drugs. 

NPCB will update the List to ensure the legitimate operation of the biosimilars. Details of this List can be seen from here:NPRA 

ChemRadar Copyright Disclaimers:

1. All texts, graphics, videos and audios with "Source: ChemRadar" on this website are copyrighted by ChemRadar. Without authorization, no media, website or individual is allowed to reproduce, link, distribute, publish, or copy any content in this website. Other media, website with our authorization shall indicate "Source: CIRS Group" when downloading or using relevant contents. Unauthorized actions will be persecuted.

2. Texts and graphics on thie website without "Source: ChemRadar" are reproduced for further information but not imply the endorsement of views or autheticity of its content. Other media, websites or individuals download or use relevant content shall remain its "Source" as prescribed in this website and bear corresponding legal responsibilities. Any unauthorized alternation to "Source: ChemRadar" may be persecuted. If you have any questions about relevant content on this website, please contact us.

3. If any content reproduced on ChemRadar raises copyright or other related issues, please contact us within two weeks.

Disclaimers
1.
CIRS aims to keep the content of this site accurate and up to date. However, CIRS makes no warranties or representations regarding the quality, accuracy, completeness or reliability of information on the site.
2.
In no event shall CIRS assume or have any responsibility or liability for any information on this site or for any claims, damages or losses resulting from their use.
3.
CIRS reserves the right, at our discretion, to change, modify, add to, or remove portions of information on this site at any time without notice.
Feedbacks
Service Hotline